Log in Free sign up

PDS Biotechnology (PDSB) News and press releases

News

From Benzinga Pro

The Daily Biotech Pulse: Veru Shares Up On COVID Candidate Update, FDA Approves Lilly's COVID Treatment, Latest On Sanofi-AstraZeneca RSV Vaccine

Biotech, Earnings, Large Cap, News, Penny Stocks, Health Care, Financing, Offerings, Contracts, Small Cap, FDA, Movers, Trading Ideas, General

Here's a roundup of top developments in the biotech space over the last 24 hours:

Recap: PDS Biotechnology Q1 Earnings

PDS Biotechnology (NASDAQ:PDSB) reported its Q1 earnings results on Wednesday, May 11, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

PDS Biotechnology Q1 EPS $(0.32) Misses $(0.22) Estimate

PDS Biotechnology (NASDAQ:PDSB) reported quarterly losses of $(0.32) per share which missed the analyst consensus estimate of $(0.22) by 45.45 percent. This is a 128.57 percent decrease over losses of $(0.14) per share

Earnings Scheduled For May 11, 2022

Earnings, News, Pre-Market Outlook, Markets

Companies Reporting Before The Bell • Great Elm Capital (NASDAQ:GECC) is expected to report earnings for its first quarter.

PDS Biotech Reports Received $1.2M Following Sale Of Its Net Operating Loss Tax Benefits Through New Jersey Economic Development Program

News, Asset Sales

PDS Biotechnology Corporation (NASDAQ:PDSB), a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted cancer immunotherapies and infectious disease vaccines based on the

What Were Your Best And Worst Stock Buys? What Does The Zinger Nation Think?

Penny Stocks, Psychology, Crowdsourcing, Top Stories, Exclusives, Personal Finance, Trading Ideas, General

Admitting to success is a lot easier than failure and when it comes to stocks, not only is there money involved, but also questioning your — or your advisor's — judgment. And then there is the advice you hear in a coffee shop. (More on that later.)

PDS Biotechnology: Q4 Earnings Insights

PDS Biotechnology (NASDAQ:PDSB) reported its Q4 earnings results on Thursday, March 31, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

The Daily Biotech Pulse: Amylyx Announces Negative Adcom Vote, Clovis Jumps On Ovarian Cancer Data, Masimo Warns Of Q1 Shortfall

Biotech, Earnings, News, Penny Stocks, Guidance, Small Cap, FDA, General

Here's a roundup of top developments in the biotech space over the last 24 hours:

Earnings Scheduled For March 31, 2022

Earnings, News, Pre-Market Outlook, Markets

Companies Reporting Before The Bell • Trevena (NASDAQ:TRVN) is likely to report earnings for its fourth quarter.

Earnings Outlook For PDS Biotechnology

PDS Biotechnology (NASDAQ:PDSB) is set to give its latest quarterly earnings report on Thursday, 2022-03-31. Here's what investors need to know before the announcement. Analysts estimate that PDS Biotechnology will report an earnings per share (EPS) of $-0.24.

The Daily Biotech Pulse: Roche's Lung Cancer Combo Therapy Flunks Late-Stage Study, Adagio Spikes On Positive COVID Antibody Data, Amylyx Awaits Adcom Verdict

Biotech, Earnings, News, Penny Stocks, Offerings, Small Cap, FDA, Top Stories, General

Here's a roundup of top developments in the biotech space over the last 24 hours.

The Week Ahead In Biotech (March 27-April 2): Lipocine, Akebia, Merck Await FDA Verdicts, Adcom Test For Amylyx, BioNTech Earnings And More

Biotech, Earnings, News, Penny Stocks, Small Cap, FDA, Top Stories, Trading Ideas, General

Biotech stocks reversed course in the week ending March 25, as an increase in risk appetite prompted traders to move money out of defensives and into risky bets.

PDS Biotechnology Earnings Conference Call Is Coming Up, Here's What You Need To Know

PDS Biotechnology (NASDAQ:PDSB) will host a conference call at 08:00 AM ET on March 31, 2022, to discuss Q4 2021 earnings results.

Earnings Scheduled For March 23, 2022

Earnings, News, Pre-Market Outlook, Markets

Companies Reporting Before The Bell • AYRO (NASDAQ:AYRO) is expected to report earnings for its fourth quarter.

Earnings Preview For PDS Biotechnology

PDS Biotechnology (NASDAQ:PDSB) is set to give its latest quarterly earnings report on Wednesday, 2022-03-23. Here's what investors need to know before the announcement. Analysts estimate that PDS Biotechnology will report an earnings per share (EPS) of $-0.24.

The Week Ahead In Biotech (March 20-26): Focus On Zogenix FDA Decision, Dermatology Conference Presentations & Earnings

Biotech, News, Penny Stocks, Small Cap, FDA, Top Stories, General

Biotech stocks rebounded along with the broader market in the week ending March 18, as risk appetite returned. Multiple conference presentations, clinical readouts and earnings news dictated sentiment during the week.

PDS Biotech Announces Achievement Of An Enrollment Objective In National Cancer Institute-Led Phase 2 Clinical Trial Of PDS0101-Based Combination In Advanced HPV-Associated Cancers

Biotech, General

PDS Biotechnology Corporation (NASDAQ:PDSB), a clinical-stage immunotherapy company developing molecularly-targeted cancer therapies and infectious disease vaccines based on the Company's proprietary

The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow

Biotech, Earnings, News, Penny Stocks, Small Cap, FDA, Top Stories, General

Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries.

Press releases

From Benzinga Pro

PDS Biotech Provides Business Update and Reports First Quarter 2022 Financial Results

Biotech, Earnings, Press Releases, General

FLORHAM PARK, N.J., May 11, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB), a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted cancer immunotherapies and

PDS Biotech Announces Two Abstracts Accepted for Presentation at the 2022 American Society of Clinical Oncology Annual Meeting

Biotech, News, Health Care, Press Releases, General

Preliminary efficacy and safety update on PDS0101 in combination with KEYTRUDA® (pembrolizumab) in first-line recurrent or metastatic HPV-positive head and neck cancerPreliminary efficacy and safety update by NCI on

PDS Biotech Chief Medical Officer, Lauren V. Wood, to Chair Session at the World Vaccine Congress

Biotech, News, Health Care, Press Releases, General

FLORHAM PARK, N.J., April 20, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB), a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted cancer immunotherapies

PDS Biotech Receives $1.2 Million After Selling Its Net Operating Loss Tax Benefits Through The New Jersey Economic Development Program

News, Contracts, Press Releases

FLORHAM PARK, N.J., April 19, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB), a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted cancer immunotherapies

PDS Biotechnology Reschedules 2021 Fourth Quarter and Full Year Financial Results and Conference Call

Biotech, News, Press Releases, General

FLORHAM PARK, N.J., March 22, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the

PDS Biotech Announces Achievement of an Enrollment Objective in National Cancer Institute-Led Phase 2 Clinical Trial of PDS0101-Based Combination in Advanced HPV-Associated Cancers

Biotech, Health Care, Press Releases, General

FLORHAM PARK, N.J., March 15, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB), a clinical-stage immunotherapy company developing molecularly-targeted cancer therapies and infectious disease

PDS Biotech Announces Preliminary Safety Data on PDS0101 in Combination With KEYTRUDA® (pembrolizumab) at the 2022 Multidisciplinary Head and Neck Cancers Symposium

Biotech, Health Care, Press Releases, General

Preliminary safety data has shown that PDS0101 in combination with Merck's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) for the treatment of recurrent or metastatic HPV16-positive head and neck cancer is likely safe